Your browser is no longer supported. Please, upgrade your browser.
EOLS Evolus, Inc. daily Stock Chart
Evolus, Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own9.60% Shs Outstand19.89M Perf Week83.93%
Market Cap473.38M Forward P/E- EPS next Y-1.37 Insider Trans- Shs Float4.85M Perf Month203.18%
Income-3.40M PEG- EPS next Q-0.31 Inst Own18.60% Short Float14.50% Perf Quarter105.17%
Sales- P/S- EPS this Y93.70% Inst Trans- Short Ratio2.78 Perf Half Y-
Book/sh2.20 P/B10.82 EPS next Y70.10% ROA- Target Price22.50 Perf Year-
Cash/sh2.49 P/C9.54 EPS next 5Y53.00% ROE- 52W Range6.75 - 19.70 Perf YTD106.96%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High20.83% Beta-
Dividend %- Quick Ratio13.80 Sales past 5Y- Gross Margin- 52W Low252.59% ATR2.23
Employees21 Current Ratio13.80 Sales Q/Q- Oper. Margin- RSI (14)81.48 Volatility20.24% 17.09%
OptionableNo Debt/Eq0.31 EPS Q/Q-54.10% Profit Margin- Rel Volume4.84 Prev Close19.36
ShortableYes LT Debt/Eq0.31 Earnings- Payout- Avg Volume252.46K Price23.80
Recom2.00 SMA20112.64% SMA50132.41% SMA200122.73% Volume1,221,733 Change22.93%
May-24-18 02:36PM  Rival to Botox Roars Back With 123% Rally Despite FDA Delay Bloomberg +22.93%
May-16-18 02:27PM  Evolus investors frown as FDA declines to approve Botox rival Reuters -26.96%
12:56PM  INVESTOR ALERT: Investigation on Behalf of Evolus Investors Announced by Holzer & Holzer Business Wire
11:13AM  Why Evolus, Inc. Is Crashing Today Motley Fool
11:07AM  Evolus investors frown as FDA declines to approve Botox rival Reuters
09:05AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:43AM  FDA declines to approve Evolus Inc's rival treatment to Botox Reuters
08:29AM  Evolus Announces Progress with DWP-450 Regulatory Submissions GlobeNewswire
07:01AM  Evolus to Provide Regulatory Update on Wednesday, May 16, 2018 GlobeNewswire
May-15-18 08:44AM  Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway Benzinga +6.78%
May-10-18 04:01PM  Evolus Reports First Quarter 2018 Financial Results GlobeNewswire +9.00%
May-07-18 07:01AM  Evolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer GlobeNewswire +20.19%
May-03-18 08:01AM  Evolus to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
Apr-23-18 07:30AM  Evolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS The Aesthetic Meeting GlobeNewswire
Apr-05-18 07:30AM  Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint GlobeNewswire -9.79%
Mar-29-18 07:30AM  Evolus Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire +8.27%
Feb-28-18 04:59PM  Who Really Owns Evolus Inc (NASDAQ:EOLS)? Simply Wall St. +5.50%
Feb-22-18 11:20AM  Evolus, Inc. (Nasdaq: EOLS) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Feb-17-18 03:00PM  Evolus Announces Presentation of Phase III European - Canadian Comparative Data PR Newswire
Feb-16-18 12:31PM  Evolus Announces Presentation of Phase III Comparative Data of PrabotulinumtoxinA and OnabotulinumtoxinA PR Newswire
Feb-12-18 11:05AM  Evolus, Inc. Announces Closing of Initial Public Offering of Common Stock PR Newswire
Feb-09-18 03:21PM  U.S. stock market chill threatens to 'put IPOs on ice' Reuters
Feb-08-18 09:42AM  U.S. IPOs start scraping through despite market jitters Reuters
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.